SCHEMBL6069978

SCHEMBL6069978

O=C(O)[C@H]1O[C@@H]1C(=O)OCCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.51
AKR1B10 O60218 4/20 0.49
AKR1B1 P15121 4/20 0.49
ESR1 P03372 2/20 0.46
ESR2 Q92731 1/20 0.46
TDP1 Q9NUW8 3/20 0.46
TSHR P16473 3/20 0.45
CYP3A4 P08684 3/20 0.45
MAPK1 P28482 3/20 0.45
HSD17B10 Q99714 3/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
ALDH1A1 P00352 2/20 0.45
TP53 P04637 2/20 0.45
HPGD P15428 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HIF1A Q16665 2/20 0.45
GLA P06280 1/20 0.45
MAOB P27338 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11193005 0.95 HCAR2 (0.51) HCAR2AKR1B10AKR1B1ESR1ESR2
SCHEMBL2386510 0.83 FABP7 (0.54) HCAR2TDP1TSHRMAPK1NPC1
SCHEMBL2386516 0.83 FABP7 (0.54) HCAR2TDP1TSHRMAPK1NPC1
SCHEMBL6816419 0.83 FABP7 (0.54) HCAR2TDP1TSHRMAPK1NPC1
SCHEMBL2386506 0.83 FABP7 (0.54) HCAR2TDP1TSHRMAPK1NPC1
Hydrochloric Acid SCHEMBL11207488 0.82 FABP7 (0.53) HCAR2TDP1TSHRMAPK1NPC1
SCHEMBL20514350 0.75 HCAR2 (0.49) HCAR2AKR1B10AKR1B1ESR1ESR2
SCHEMBL31424021 0.75 PTGES (0.53) HCAR2AKR1B10AKR1B1ESR1ESR2
SCHEMBL3504514 0.75 HCAR2 (0.51) HCAR2AKR1B10AKR1B1ESR1ESR2
SCHEMBL983427 0.73 HCAR2 (0.61) HCAR2AKR1B10AKR1B1ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7056947-B2 For inhibiting (cysteine) proteases/caspases; for treatment of viral infections, stroke, neurodegenerative disease, and inflammatory diseases GEORGIA TECH RESEARCH CORP. (US) 2006-06-06 US disclosed
US-20040048327-A1 Aza-peptide epoxides NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-03-11 US disclosed
WO-2004005270-A1 AZA-PEPTIDE EPOXIDES GEORGIA TECH RESEARCH CORPORATION (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048327-A1 Aza-peptide epoxides ANPEP, ENPEP, TMPRSS15 HCAR2 2884/4885AKR1B10 2857/4885AKR1B1 2464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.